251 related articles for article (PubMed ID: 24416238)
1. Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis.
Peng Z; Zhu Y; Wang Q; Gao J; Li Y; Li Y; Ge S; Shen L
PLoS One; 2014; 9(1):e84502. PubMed ID: 24416238
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.
Nakajima M; Sawada H; Yamada Y; Watanabe A; Tatsumi M; Yamashita J; Matsuda M; Sakaguchi T; Hirao T; Nakano H
Cancer; 1999 May; 85(9):1894-902. PubMed ID: 10223227
[TBL] [Abstract][Full Text] [Related]
3. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.
Yang Y; Wang C; Dai C; Liu X; Li W; Huang M; Zhao X; Ji D; Li J; Guo W
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):547-557. PubMed ID: 33693450
[TBL] [Abstract][Full Text] [Related]
4. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.
An X; Wang F; Shao Q; Wang FH; Wang ZQ; Wang ZQ; Chen C; Li C; Luo HY; Zhang DS; Xu RH; Li YH
Cancer; 2014 Mar; 120(5):675-82. PubMed ID: 24804300
[TBL] [Abstract][Full Text] [Related]
5. C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.
Yu S; Yu Y; Zhao N; Cui J; Li W; Liu T
PLoS One; 2013; 8(11):e79137. PubMed ID: 24223894
[TBL] [Abstract][Full Text] [Related]
6. MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.
Zhang J; Guo L; Liu X; Li W; Ying J
Oncotarget; 2017 Feb; 8(6):10264-10273. PubMed ID: 28052014
[TBL] [Abstract][Full Text] [Related]
7. MET expression and amplification in patients with localized gastric cancer.
Janjigian YY; Tang LH; Coit DG; Kelsen DP; Francone TD; Weiser MR; Jhanwar SC; Shah MA
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1021-7. PubMed ID: 21393565
[TBL] [Abstract][Full Text] [Related]
8. Relationship between epithelial cell adhesion molecule (EpCAM) overexpression and gastric cancer patients: A systematic review and meta-analysis.
Dai M; Yuan F; Fu C; Shen G; Hu S; Shen G
PLoS One; 2017; 12(4):e0175357. PubMed ID: 28403178
[TBL] [Abstract][Full Text] [Related]
9. The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis.
Qian H; Appiah-Kubi K; Wang Y; Wu M; Tao Y; Wu Y; Chen Y
Crit Rev Oncol Hematol; 2018 Jul; 127():15-28. PubMed ID: 29891108
[TBL] [Abstract][Full Text] [Related]
10. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
Catenacci DV; Ang A; Liao WL; Shen J; O'Day E; Loberg RD; Cecchi F; Hembrough T; Ruzzo A; Graziano F
Cancer; 2017 May; 123(6):1061-1070. PubMed ID: 27926778
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.
Janbabai G; Oladi Z; Farazmandfar T; Taghvaei T; Naghshvar F
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1945-52. PubMed ID: 25820598
[TBL] [Abstract][Full Text] [Related]
12. Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
Peng Z; Li Z; Gao J; Lu M; Gong J; Tang ET; Oliner KS; Hei YJ; Zhou H; Shen L
Mol Cancer Ther; 2015 Nov; 14(11):2634-41. PubMed ID: 26330547
[TBL] [Abstract][Full Text] [Related]
13. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.
Lee J; Seo JW; Jun HJ; Ki CS; Park SH; Park YS; Lim HY; Choi MG; Bae JM; Sohn TS; Noh JH; Kim S; Jang HL; Kim JY; Kim KM; Kang WK; Park JO
Oncol Rep; 2011 Jun; 25(6):1517-24. PubMed ID: 21424128
[TBL] [Abstract][Full Text] [Related]
14. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
[TBL] [Abstract][Full Text] [Related]
15. MET in gastric cancer--discarding a 10% cutoff rule.
Metzger ML; Behrens HM; Böger C; Haag J; Krüger S; Röcken C
Histopathology; 2016 Jan; 68(2):241-53. PubMed ID: 26033401
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
17. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
18. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.
Kim HS; Chon HJ; Kim H; Shin SJ; Wacheck V; Gruver AM; Kim JS; Rha SY; Chung HC
J Surg Oncol; 2018 Jun; 117(8):1679-1686. PubMed ID: 29790169
[TBL] [Abstract][Full Text] [Related]
19. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features.
Tsugawa K; Yonemura Y; Hirono Y; Fushida S; Kaji M; Miwa K; Miyazaki I; Yamamoto H
Oncology; 1998; 55(5):475-81. PubMed ID: 9732228
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.
Carneiro F; Sobrinho-Simoes M
Cancer; 2000 Jan; 88(1):238-40. PubMed ID: 10618628
[No Abstract] [Full Text] [Related]
[Next] [New Search]
